Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Profit After Tax (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Profit After Tax data on record, last reported at -$36.8 million in Q3 2025.

  • For Q3 2025, Profit After Tax fell 46.45% year-over-year to -$36.8 million; the TTM value through Sep 2025 reached -$126.4 million, down 88.48%, while the annual FY2024 figure was -$85.0 million, 94.95% down from the prior year.
  • Profit After Tax reached -$36.8 million in Q3 2025 per DNTH's latest filing, down from -$31.6 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$4.9 million in Q1 2022 and bottomed at -$36.8 million in Q3 2025.
  • Average Profit After Tax over 4 years is -$17.6 million, with a median of -$14.8 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: rose 7.91% in 2023, then crashed 168.67% in 2024.
  • A 4-year view of Profit After Tax shows it stood at -$10.1 million in 2022, then decreased by 4.62% to -$10.6 million in 2023, then tumbled by 168.67% to -$28.5 million in 2024, then dropped by 28.98% to -$36.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$36.8 million in Q3 2025, -$31.6 million in Q2 2025, and -$29.5 million in Q1 2025.